Premium
The prognostic significance of serum levels of soluble intercellular adhesion molecules‐1 in patients with primary extranodal non‐Hodgkin lymphomas
Author(s) -
Lei Kenny I. K.,
Johnson Philip J.
Publication year - 2000
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(20000915)89:6<1387::aid-cncr24>3.0.co;2-3
Subject(s) - medicine , pathology , intercellular adhesion molecule 1 , intracellular , primary (astronomy) , adhesion , cell adhesion molecule , immunology , biochemistry , biology , chemistry , physics , organic chemistry , astronomy
BACKGROUND Elevated levels of soluble intercellular adhesion molecules (sICAM)‐1 in serum have been shown to be associated with poor prognosis in Hodgkin disease and non‐Hodgkin lymphomas. However, little is known about the significance of serum sICAM‐1 levels in extranodal lymphomas. The objective of this study was to examine the sICAM‐1 levels in patients with extranodal lymphomas and the correlation with clinical features and outcome. METHODS The serum levels of sICAM‐1 were measured in stored serum samples of 88 patients with primary extranodal lymphomas at presentation using enzyme‐linked immunoassay. The correlation between serum sICAM‐1 levels and clinical characteristics, pathologic features, and disease outcome were retrospectively analyzed. RESULTS Serum sICAM‐1 levels in patients with extranodal lymphomas (mean, 372 ± 198.8 ng/mL; interquartile range, 252–466 ng/mL) were significantly higher than that of healthy control subjects (mean, 214 ± 78.5 ng/mL; interquartile range, 160–241 ng/mL; P < 0.0001). High serum sICAM‐1 levels (≥ 371 ng/mL) were significantly associated with B‐symptoms, elevated lactate dehydrogenase level, advanced stage (III/IV; Ann Arbor Staging System), and poor response to therapy. Univariate analysis demonstrated a significantly poorer 5‐year disease free (41% vs. 64%; P = 0.01) and overall (44% vs. 73%; P = 0.003) survival in patients with high serum sICAM‐1 as compared with those with normal sICAM‐1. In multivariate analysis, both disease free ( P = 0.0085) and overall ( P = 0.0003) survival were independently associated with high serum sICAM‐1 levels. CONCLUSIONS Serum sICAM‐1 levels are elevated in patients with extranodal lymphomas. In these individuals, high serum sICAM‐1 levels are associated with adverse disease features and poor outcome. Cancer 2000;89:1387–95. © 2000 American Cancer Society.